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ABSTRACT
The so-called idiopathic trigeminal neuralgia is easily diagnosed by the clinical history of the patient and 
present a constant cause, a neurovascular conflict in the cerebellopontine angle in the majority of cases, 
which is clearly identified by MRI assessment. Knowing the cause, after a trial period with a medical treat-
ment, a curative surgical solution can be now offered to the patient when the medications do not provide a 
pain-free result or when the patients wish a more definitive solution. Combining the use of both operating 
microscope and endoscope increases the efficiency of the neurovascular decompression and decreases dras-
tically the potential morbidity of the surgical procedure. From 355 patients suffering of trigeminal neural-
gia who underwent endoscope-assisted retrosigmoid approach, the authors present their experiences and 
results.
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INTRODUCTION
The classical trigeminal neuralgia (TN) is a mo-
notonously repetitive severe shooting pain in the sen-
sitive distribution of the trigeminal nerve (V), eas-
ily diagnosed by the history obtained from the pa-
tient. It was also called essential or idiopathic neural-
gia, because the cause has long been misunderstood. 
Currently, there is a considerable evidence that in the 
most of the cases cranial nerve (CN) V is compressed 
by a vascular structure in the cerebellopontine an-
gle (CPA). The classical typical essential or idiopathic 
trigeminal neuralgia can “be tied into a single etiolog-
ic package” (1) of “neurovascular compression syn-
drome”.  Knowing the cause, a curative solution can 
finally be proposed to the patient.
The medical treatment with anticonvulsant 
drugs has been developed primarily as a consequence 
of Trousseau’s hypothesis: tic douloureux or epilepti-
form neuralgia (2), that the attacks of pain suffered 
by the patients are due to paroxysmal activity in the 
trigeminal system similar to the cerebral paroxysmal 
discharges in epilepsy (3). However, the etiology and 
pathogenesis of trigeminal neuralgia has remained a 
subject of controversy.
Dandy (4), Gardner (5), and Jannetta (6) were 
the pioneers to promote the peripheral concept of 
neurovascular compression or cross-compression 
syndrome and to perform surgical decompression 
with the resolution of the patient’s symptoms. Af-
ter a long period of little acceptance, the neurovas-
cular decompression procedure has been popular-
ized by several technological improvements: MRI as-
sessment in T2 sequences, minimally invasive tech-
niques with endoscope-assisted microsurgery (7,8).
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MRI Assessment 
MRI is an essential element in the work-up of 
these pathologies. MRI is able to reproduce the anat-
omy of the CPA and to demonstrate the presence of 
a neurovascular conflict (9,10). It also eliminates oth-
er potential causes such as a tumor process or multi-
ple sclerosis. MRI establishes the diagnosis, accurate-
ly assesses the responsible vessels, and finally dictates 
the indication for surgery (9).
MRI in both T1 and T2 three-dimensional 
Fourier transform (3DFT) sequences is the most ef-
fective method of delineating both the cranial nerves 
and the surrounding vascular structures in the CPA. 
The protocol for imaging that we follow includes be-
ginning with whole brain T2 or FLAIR sequence to 
exclude multiple sclerosis, followed by axial & cor-
onal Tl (preferably with contrast to look for venous 
cause) imaging of the brainstem and CPA cistern to 
look for cranial neuritis, perineural and cisternal tu-
mors. High-resolution thin-section T2 imaging of 
the brainstem and CPA cistern is performed next 
and is the best sequence to look for an offending ar-
tery. The T2 is carried out using constructive inter-
ference in steady state (3D CISS) sequences offering 
high spatial resolution and excellent contrast resolu-
tion and depict both the artery and the vein respon-
sible for the neurovascular conflict. Imaging of the 
CPA is done with serial thin slices, preferably of 0.4 
mm thickness.
To confirm the diagnosis, the single presence of 
a neurovascular contact is not sufficient. Several ra-
DIAGNOSIS
Clinical Features  
Trigeminal neuralgia is a disease of mid-life. 
Three out of four times the pain is felt after 50 years, 
with an average of 55 years and range of 18 to 83 
years. 
The pain of TN is paroxysmal, sharp, often 
compared to electric shock, brief episodes of pain 
with periods of remission in between but the patient 
has anxiety for the next episode. The pain common-
ly strikes the third (mandibular) division of the nerve 
along the jaw and the lower teeth or tongue and less 
commonly affects the second (maxillary) and first 
(ophthalmic) division. The pain is provoked by 
speech, chewing, brushing teeth, wind or by the light 
tactile of the “trigger zone” (unilateral cheek and/or 
nose). The phenomenon disappears at night, during 
sleep. Trigeminal neuralgia usually begins as a re-
lapsing disease with pain-free intervals, which grow 
shorter. There is no sensory deficit, no decrease in 
corneal reflex, and no symptom in the other crani-
al nerve territories. 
It is essential to distinguish typical TN from the 
atypical one, secondary or symptomatic TN with a 
constant background burning or aching pain or with 
sensory loss or without trigger zone. Generally, the 
underlying cause is not a neurovascular conflict and 
does not respond to surgical decompression. 
Fig. 1. A. MRI, axial T2 CISS sequence showing a perpendicular contact between the SCA (white arrow) and its branches 
(black arrows) with the trigeminal nerve at its cistern course, and a reduction in diameter of the trigeminal nerve 
compared to the opposite side. B. Endoscopic view in same patient of the distorted trigeminal nerve (5) by the SCA.
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diological criteria are required including a perpen-
dicular contact between the vascular loop and the 
trigeminal nerve at its root entry zone (REZ), visu-
alized along two different perpendicular planes, and 
a distortion of the nerve or other neural structures. 
For the trigeminal nerve, the reduction in diameter is 
an additional criterion. The most common offending 
vessel is the superior cerebellar artery (SCA) (Fig. 1A 
and 1B), but in around 20% of cases, a venous struc-
ture (aberrant trigeminal vein) might be the cause of 
the conflict, either alone or in combination with an 
artery, and it is visible only on T1 with gadolinium. 
The axial plane offers the most comprehensive and 
demonstrative images, coronal and sagittal planes 
confirm and precisely predict the course of the of-
fending artery (Fig. 2, Fig. 3).
The offending vessels are, in order of frequency, 
SCA (79%), an aberrant trigeminal vein (29%), then 
the ectasia of the vertebrobasilar artery (Fig. 4. A, B, 
C) and anterior inferior cerebellar artery (AICA) in 
5%. The exact site of the conflict on the trigeminal 
nerve is at root entry zone (REZ) in 33% of cases, at 
the cisternal course of the nerve in 50% of the cases 
and at the entrance of the nerve in Meckel’s cave in 




Typical TN usually responds well to medical 
treatment trial with carbamazepine, at least initial-
ly and is pathognomonic of diagnosis. Carbamaze-
pine is started as a first-line drug in doses of 100 mg 
bid and increased as per requirement up to 800–1000 
mg per day based on the tolerance of the patient. 
Even though carbamazepine has stronger evidence 
(11), oxcarbazepine in the doses of 600–1800 mg per 
day is generally considered to be better tolerated (12). 
Fig. 2. MRI coronal plane, T2 CISS sequence showing 
cross-compression of the right trigeminal nerve
Fig. 3. MRI sagittal plane, T2 CISS sequence showing the 
trigeminal nerve from the Meckel cave to the pons crossed 
by the SCA as shown in the endoscopic picture of the right 
cerebellopontine angle (CPA) with both caudal and rostral 
branches of SCA impinging into V.
Fig. 4. A. MRI axial T2 CISS sequence. B. T1 gadolinium-enhanced sequence showing an ectasia of the vertebral arteries 
distorting the right trigeminal nerve. C. Endoscopic view VA (right vertebral artery), cVA (contralateral vertebral artery), 
V (trigeminal nerve), DV (Dandy vein). 
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The second-line drug therapy includes add-on ther-
apy with lamotrigine (400 mg/day) or baclofen (40-
80 mg/day) (13,14). As the time passes, however, for 
many of the patients, the drug become ineffective or 
the patient develops adverse effects to the drug. 
Second Line: Curative
Surgery is indicated after failure or side effects 
from the anticonvulsant treatment or when the pa-
tient wants a more permanent solution. Endoscope-
assisted microvascular decompression may be con-
sidered as a treatment of choice providing the only 
curative solution with a high long-term success rate.
Third Line: Palliative
Radiofrequency thermocoagulation, glycerol 
rhizotomy, balloon compression or stereotactic radio-
therapy, neuromodulation techniques like Gasserian 
ganglion stimulation (15), peripheral nerve stimula-
tion (16), and invasive motor cortex stimulation (17), 
and non-invasive cortex stimulation (18) are consid-
ered palliative options. Botulinium neurotoxin type 
A (BoNT-A) has been experimentally used for the 
treatment in recent studies (19). Such treatments by-
pass the cause, the sensory disturbance is constant, 
the pain recurrence is higher and is not easy to solve 
by microvascular decompression (MVD) performed 
after percutaneous ablative techniques or radiothera-
py. It can be indicated in the rare case of failure after 
MVD or in a patient with comorbidity.
Endoscope-Assisted Microvascular Decom-
pression Surgery
The surgical approach that we follow is key-
hole minimally invasive retrosigmoid approach with 
the patient in the dorsal decubitus position and his 
head non-fixed, flexed, and turned to the contralat-
eral side.
The retromastoid, retrosigmoid craniotomy is 
centered on the emissary vein and its size is usually 
15 to 20 mm. A “protected” surgical corridor allows 
to safely access the cranial nerves crossing the cere-
bellopontine angle. The 30 degrees angled rigid en-
doscope, 4 mm in diameter, offers a panoramic view 
to identify the course of the vascular structure sur-
rounding the trigeminal nerve from the pons medi-
ally to the Meckel cave laterally. The offending artery 
is elevated from the nerve and the pons by dissecting 
the arachnoid adherences between CN V and the of-
fending vascular loop. The SCA (main trunk or with 
its two branches) is the most common cause and is 
Fig. 5. Endoscope-assisted retrosigmoid approach for a right trigeminal neuralgia: A. The offending structure is a 
compressive loop of the superior cerebellar artery. B. After decompression of the two branches of SCA away from CN V 
towards the tentorium with placement of Teflon patches.
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carefully mobilized from the nerve towards the ten-
torium and maintained far from any contact with 
the nerve using fibrin glue and small pieces of Tef-
lon (Fig. 5 A, B). If it is not possible to mobilize the 
artery further away towards the tentorium, the gap 
between the offending artery and the nerve should 
be insulated with a Teflon patch. The vein is rarely 
mobilized and decompressed with Teflon but mainly 
coagulated with bipolar coagulation (Fig. 6 A, B). No 
facial paralysis or hearing loss were present in our se-
ries. Post-operative complications were limited to a 
cerebrospinal fluid (CSF) leak in 2% of the patients 
and were solved within one week. A minimally inva-
sive approach as well as its meticulous closure is a key 
point in preventing complications.
RESULTS OF VASCULAR DECOM-
PRESSION FOR TRIGEMINAL 
NEURALGIA
In the literature, the success of the procedure 
varies from 73% to 97% (20–24) and confirms that 
the most sustained pain relief is reported following 
microvascular decompression (25). We have a com-
bined experience of 355 MVDs on patients suffering 
from trigeminal neuralgia resistant to medical treat-
ment. The oldest patient was 87 years old. The com-
plete resolution of the pain was immediate in 88% 
and required revision surgery to increase the overall 
successful result in 93%. The recurrence after imme-
diate postoperative relief is mentioned in all MVD 
series. The recurrence occurred in 12% of our pa-
tients (26), between 3 months to 2 years after initial 
surgery. Its main cause is the fibrous tissue around 
the trigeminal nerve inducing a new neurovascular 
conflict or embedding the Teflon in the nerve. A re-
vision surgery is recommended and accepted by a pa-
tient who has already experienced a pain-free period.
CONCLUSION
In our neuro-otological experience of more 
than 1200 retrosigmoid approach surgeries in last 
thirty years for vascular compression syndromes, we 
have very little morbidity. This should be the rule in 
the functional surgical indications. The most com-
mon surgical cause of incomplete cure is misjudge-
ment of the real offending vessel and incomplete 
or improper replacement of the conflict vessel. The 
complementary use of endoscope with the operating 
microscope enhances the chances of visualization of 
the offending vessels without increasing the amount 
of retraction of the cerebellum and thus reducing the 
Fig. 6. Endoscope-assisted retrosigmoid approach for a left trigeminal neuralgia: A. Aberrant trigeminal vein crossing 
inferiorly CN V close to its Meckel cave entrance. B. After coagulation of the offending vein, the trigeminal nerve is free 
of any vascular contact. The Dandy vein is preserved.
Scripta Scientifica Medica, 2021;53(2):48-54
Medical University of Varna 53
Jacques Magnan, Bhavin Parikh, Pradeep Vundavalli
chances of side effects. Both improvements in anes-
thesia and in surgery offer a definitive treatment in 
patients suffering from trigeminal neuralgia at any 
age. 
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